Study validates clinical utility of pan-tumor predictive biomarker for checkpoint inhibitor immunotherapy benefit
A new study validating the clinical utility of a proprietary pan-solid tumor predictive biomarker for anti-PD-1/PD-L1 checkpoint inhibitor monotherapy benefit—called Immunotherapy Response Score (IRS)—was published in ...
Feb 7, 2023
0
1